Brought to you by 
SciGen grants Chinese SciLin rights to Bayer Schering
24 Aug 2009
Executive Summary
For the next 15 years, Bayer Schering Pharma has exclusive rights in China to sell SciLin, a recombinant human insulin produced by SciGen (genetically engineered products mainly for metabolic and infectious diseases), which is majority owned by Polish biotech Bioton SA.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SciGen grants Chinese SciLin rights to Bayer Schering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice